The Latest

  • A clear drop with a dollar symbol is pipetted into a test tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Biotech startup funding gap widens despite rebound in VC investment

    Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Heart drug developer Braveheart Bio and and immune disease biotech Attovia Therapeutics have become the second and third startups to outline IPO proposals this week.

    Updated 8 hours ago
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the third quarter of 2026

    A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.

    FDA
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

    Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

  • A closeup of an entryway that reads the Federal Trade Commission.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CVS Caremark reaches settlement with FTC over insulin suit

    Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on standard formularies.

  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Q32 bounces back to claim study success for alopecia drug

    Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Including three deals announced Tuesday, Chinese drugmakers have formed more than 100 licensing pacts with their U.S. and European counterparts since the start of 2025, BioPharma Dive data show.

    Updated July 14, 2026
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Draig bags another $65M to speed testing of brain drugs

    The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder. 

  • An illustration of pain in the colon.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Freenome colorectal cancer test data improve on earlier results

    The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Agenus surges on study pivot; Apnimed lines up an IPO

    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Hansoh ADC extends survival in lung cancer study

    GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche scraps two Ionis-partnered Huntington’s drugs

    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Ionis drug fails big heart disease study in major setback

    Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

  • paperwork art
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    HHS plan to speed drug research won’t remove ‘self-inflicted’ delays

    U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

    FDA
  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    On back-to-back days, AI drug discovery specialist Chai Discovery and radiopharmaceuticals developer AdvanCell raised two of the year’s top venture rounds involving the investment firms BioPharma Dive tracks.

    Updated 5 hours ago
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip
    China competition

    AstraZeneca, GSK intensify China ties with Sino Biopharm deals

    The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK ends brain drug alliance with Alector

    Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

    An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Vera Therapeutics wins FDA nod for closely watched kidney disease drug

    The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year. 

  • Vertex
    Image attribution tooltip
    Permission granted by Vertex
    Image attribution tooltip

    Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

    Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Kailera says obesity pill succeeds in late-stage trial in China

    The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Cancer, immune drugmakers dominate VC funding so far in 2026

    Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis to acquire ADC developer in a deal worth up to $1.5B

    The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.